By Brad Sorensen, CFA

NASDAQ:TELO

READ THE FULL TELO RESEARCH REPORT

Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. While that might not sound groundbreaking on the initial read, understanding what telomeres do and how they are involved in human aging and quality of life will likely lead investors to where it has led us—a place with great excitement about the potential of such a breakthrough. The explanation of telomeres is more fully explained below, but briefly, telomeres are the end caps of chromosomes and naturally shorten as humans age. Lengthening these telomeres could result in longer life and the potential treatment of age-related diseases.

Preclinical tests have shown evidence that Telomir-1 can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company just released result from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”

Of course, there’s still a long way to go before we get to that point, with preclinical testing still going on. The company is currently diving deeper into understanding how Telomir-1 works, but the company does know that the compound is an iron chelator. High levels of iron can accelerate the shortening of telomeres and cause a plethora of other health issues. Telomir is testing Telomir-1 on a variety of both human and canine conditions, including cancer, osteoarthritis and progeria, which is a rare, fatal condition that strikes in childhood and resembles premature aging. The potential of this drug is obvious and company management plans to aggressively pursue FDA approval and is planning on both human and animal IND filings in 1Q 2025. While there are multiple steps involved in the approval process, our confidence in the process is elevated for TELO due to the team they’ve established. Company management recently announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor.

Dr. Angel, in collaboration with Telomir’s senior management, will look to expedite the pre-clinical and clinical path of Telomir-1. Dr. Angel is known for his lengthy career in pharmaceutical innovation and was previously the Head of Pharmacology at Synthelabo (now part of Sanofi-Aventis), where he played important roles in developing several groundbreaking drugs, including the widely used sleep aid, Ambien (zolpidem) and the BPH drug, Uroxatral (Alfuzosin).

Beyond Synthelabo, Dr. Angel has held leadership roles in multiple pharmaceutical companies, where he guided drug candidates from conception through clinical trials and into the market. Dr. Angel has been previously President and CEO of Accellta, a company that offers revolutionary solutions for stem cell culturing and development. His work has encompassed a broad range of therapeutic areas, including neurology, psychiatry, metabolic diseases, urology and stem cell technology.

It's this extensive experience and record of success, combined with the test results we’ve seen at this stage of the process that makes us get excited about the potential for Telomir-1 and the company that develops it. We urge investors who have a higher risk tolerance to take a look at TELO and consider investing in a company at a very early stage that has a large potential upside, with a low float and positive news flow likely in the near future, providing potential fuel to the stock.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.